GlobeNews Wire

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical…

10 months ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…

10 months ago

XRP News: Vaultro Finance Presale on XRP ledger Skyrockets Past 50%, As Investors Race to Own $VLT Token

SINGAPORE , June 15, 2025 (GLOBE NEWSWIRE) -- Vaultro Finance has just announced a landmark achievement in its public sale…

10 months ago

BestOnlineSportsbooks.info Publishes New Report on the Rise of Cryptocurrency in U.S. Sportsbooks

Saint John, Antigua and Barbuda, June 14, 2025 (GLOBE NEWSWIRE) -- BestOnlineSportsbooks.info, a recognized source for sports betting industry insights,…

10 months ago

DNMiner Launches Revolutionary $100 Welcome Bonus on AIPowered Cloud Mining Platform

Short-term crypto mining contracts deliver daily returns with no hardware setup June 14, 2025 01:42 ET  | Source: DNMiner New…

10 months ago

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…

10 months ago

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

10 months ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…

10 months ago

Ripplecoin Mining Free Cloud Mining App, High-yield Cloud Mining Investment Guide for BTC and XRP Holders

Free mobile cloud mining app, investors can easily mine on their mobile phones anytime and anywhere without hardware, and steadily…

10 months ago

From LINE to Global: Slime Miner Hits $2M Monthly and Leads Kaia Growth

Singapore , June 14, 2025 (GLOBE NEWSWIRE) -- The Web3 hit game leads Kaia’s growth and sets a new benchmark…

10 months ago